Tipsheet
What matters at India’s listed companies
Hospital & Healthcare · Small cap

Suraksha Diagnostic cools growth targets to 15% for FY27

Management pivots on performance metrics while shifting toward public-private partnerships, drawing scrutiny.

5 earlier stories on Suraksha Diagnostic Ltd.
Mkt cap₹1,415 cr
P/E43.95×
ROE15.07%
Debt / eq.0.03
Div yld0.18%
15% Revenue growth guidance for FY27, down from 22.5% in FY26.

What's new

  • Revenue growth target drops to 15% from 22.5% in FY26.
  • Management targets a 33% EBITDA margin, up from 31.5% last year.
  • Company plans to open 14 new centres with ₹70 cr in capex.

Why this matters

The company’s sudden dismissal of patient volume as a core metric leaves shareholders guessing about how it tracks success. Re-entering public-private partnerships after previous denials suggests a lack of clarity in long-term goals.

What we're watching

  • Whether the new centres hit the targeted 33% EBITDA margin.
  • Future profitability disclosures on public-private contracts.
  • Management’s rationale for ignoring patient volume in upcoming results.

The full read

Suraksha Diagnostic enters FY27 with a more conservative outlook. Management projected 15% revenue growth for the year, a drop from the 22.5% expansion recorded in FY26. To hit their 33% EBITDA margin goal, the firm must lift returns by 150 basis points from last year’s 31.5% print. A ₹70 crore capex plan to build 14 new centres is the engine for this goal.

Then the mood soured.

Management dismissed patient volume as a primary performance metric, despite using it as a key yardstick in previous quarters. The company also signaled an appetite for public-private partnership contracts, contradicting earlier statements that it would avoid such agreements. The market is left with a firm that is growing slower and changing its playbook mid-stream. It is an uncomfortable shift.

Mentioned: Suraksha Diagnostic · FY26 Results · FY27 Outlook
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Suraksha Diagnostic Ltd.

Hospitals
₹1,413 cr
P/E 43.90×

Latest quarter · Mar 2026

Sales₹81 cr
Net profit₹6 cr
Op. margin+29.9%
EPS₹1.21

Strength & growth

Debt / equity0.03×
Current ratio1.10×
  1. 22 May 2026 · 1:12 PM IST Suraksha Diagnostic cools growth targets to 15% for FY27
  2. 45d ago Suraksha Diagnostic transcript confirms previously issued FY27 guidance
  3. 51d ago Suraksha's revenue grew 22.5%, but profit fell 14% in Q4.
  4. 51d ago Suraksha Diagnostic revenue lifts 21% as margins tighten
  5. 51d ago Suraksha Diagnostic's revenue grows 20%. Profit doesn't follow.